Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer

JOURNAL OF THORACIC ONCOLOGY(2017)

Cited 0|Views22
No score
Key words
osimertinib,T790M,EGFR-TKI
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined